Personalis, Inc. (PSNL)
Market Cap | 62.33M |
Revenue (ttm) | 74.15M |
Net Income (ttm) | -92.61M |
Shares Out | 51.94M |
EPS (ttm) | -1.90 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 86,261 |
Open | 1.180 |
Previous Close | 1.195 |
Day's Range | 1.170 - 1.220 |
52-Week Range | 0.891 - 2.430 |
Beta | 1.87 |
Analysts | Strong Buy |
Price Target | 5.00 (+316.67%) |
Earnings Date | Aug 6, 2024 |
About PSNL
Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal res... [Read more]
Financial Performance
In 2023, Personalis's revenue was $73.48 million, an increase of 12.97% compared to the previous year's $65.05 million. Losses were -$108.30 million, -4.43% less than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for PSNL stock is "Strong Buy." The 12-month stock price forecast is $5.0, which is an increase of 316.67% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/f/w/press16-2485544.jpg)
Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that Chris Hall, CEO and President, will join a panel and speak at the TD C...
![](https://cdn.snapi.dev/images/v1/y/s/conf19-2477562.jpg)
Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it has updated the ASCO data highlights conference call to Friday, Jun...
![](https://cdn.snapi.dev/images/v1/u/g/press13-2462498.jpg)
ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) announced today that data presented at the American Society for Clinical Oncology (ASCO) oral podium talks in Chicago, IL demonstrated...
![](https://cdn.snapi.dev/images/v1/a/6/press8-2456086.jpg)
Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the commencement of commercialization efforts by Tempus for NeX...
![](https://cdn.snapi.dev/images/v1/4/s/press10-2443430.jpg)
Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two podium presentations and multiple posters featuring da...
![](https://cdn.snapi.dev/images/v1/m/0/press3-2443463.jpg)
Antares Bolsters Private Wealth Team with Three New Senior Appointments
CHICAGO--(BUSINESS WIRE)--Antares Capital (“Antares”), a leading alternative asset manager with more than $69B in capital under management and administration, today announced three new senior hires to...
![](https://cdn.snapi.dev/images/v1/y/g/press3-2438002.jpg)
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors grant...
![](https://cdn.snapi.dev/images/v1/b/q/press17-2421701.jpg)
Personalis Reports First Quarter 2024 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2024 ended March 31, ...
![](https://cdn.snapi.dev/images/v1/1/s/conf5-2389271.jpg)
Personalis to Announce First Quarter 2024 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2024 financial results on Wednesday,...
![](https://cdn.snapi.dev/images/v1/q/k/conf7-2347178.jpg)
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 23rd Annual Needham Virtual He...
![](https://cdn.snapi.dev/images/v1/8/g/press17-2346239.jpg)
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that a podium talk and multiple abstracts featuring data for th...
![](https://cdn.snapi.dev/images/v1/u/f/press17-2341860.jpg)
Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a new publication validating the company's NeXT Personal test, ...
![](https://cdn.snapi.dev/images/v1/u/v/press12-2299578.jpg)
Personalis Reports Fourth Quarter and Full Year 2023 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended Dec...
![](https://cdn.snapi.dev/images/v1/i/r/conf11-2276683.jpg)
Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full year 2023 financial result...
![](https://cdn.snapi.dev/images/v1/a/q/conf8-2254070.jpg)
Personalis to Participate at Upcoming Investor Conferences
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the following investor confere...
![](https://cdn.snapi.dev/images/v1/t/2/press3-2250816.jpg)
Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology
FREMONT, Calif. & SAN DIEGO--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, and ClearNote Health, Inc., a pioneer in epigenomic technologies, today unveile...
![](https://cdn.snapi.dev/images/v1/w/y/press16-2230671.jpg)
Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced it has received a final Medicare coverage determination for its...
![](https://cdn.snapi.dev/images/v1/s/y/press10-2218189.jpg)
Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full ye...
![](https://cdn.snapi.dev/images/v1/x/m/press7-2181987.jpg)
Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc., a leader in advanced genomics for precision oncology (Nasdaq: PSNL), disclosed a reduction in headcount impacting approximately 20% of the company's...
![](https://cdn.snapi.dev/images/v1/h/y/press7-2174798.jpg)
Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing
FREMONT, Calif. & CHICAGO--(BUSINESS WIRE)--Personalis, Inc., a leader in advanced genomics for precision oncology (Nasdaq: PSNL), and Tempus Labs, Inc., a leader in artificial intelligence and precis...
![](https://cdn.snapi.dev/images/v1/k/m/press20-2145119.jpg)
Personalis Reports Third Quarter 2023 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2023...
![](https://cdn.snapi.dev/images/v1/l/j/press12-2122644.jpg)
Personalis Launches NeXT Personal® Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the launch of the Early Access Program for NeXT Personal Dx, a ...
![](https://cdn.snapi.dev/images/v1/4/l/conf3-2118374.jpg)
Personalis to Announce Third Quarter 2023 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2023 financial results o...
![](https://cdn.snapi.dev/images/v1/s/g/press18-2114207.jpg)
Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in precision oncology, today announced the presentation of initial findings from its work with the groundbreaking TRACERx lu...
![](https://cdn.snapi.dev/images/v1/f/o/press13-2110681.jpg)
Personalis Announces Late-Breaking NeXT Personal Abstract and Proffered Paper Presentation at ESMO 2023
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in precision oncology, today announced that a late-breaking abstract featuring data for the company's NeXT Personal® whole g...